ARTICLE | Finance
Vive la biotech
Why investors are paying more attention to French biotech
November 5, 2016 9:06 PM UTC
The French biotech sector has historically lagged other European countries such as the U.K. and Germany in both financings and deals. But a fledgling group of public bellwethers and a crop of innovative private companies are wooing and winning fresh capital.
France’s bellwethers - CAR T play Cellectis S.A., allergy company DBV Technologies S.A., NASH play Genfit S.A., and immuno-oncology company Innate Pharma S.A. - are driving interest in the French biotech sector as they near Phase III readouts or advance differentiated assets in hot disease areas...